AWH — Aspira Women's Health Share Price
0.000.00%
Last trade - 00:00- $43.08m
- $42.75m
- $9.15m
- 32
- 11
- 44
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1561.85% | ||
| Return on Equity | -723.45% | ||
| Operating Margin | -195.02% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.54 | 4.65 | 6.81 | 8.18 | 9.15 | 10.97 | 19.67 | 24.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.
Directors
- James Lafrance NEC (62)
- Valerie Palmieri PRE (59)
- Robert Beechey CFO (58)
- Mint Merchant GCN
- Veronica Jordan IND (70)
- Nicole Sandford IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 23rd, 2000
- Public Since
- September 29th, 2000
- No. of Shareholders
- 40
- No. of Employees
- 64
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 12,344,104
- Address
- Suite 100, AUSTIN, 78738
- Web
- https://aspirawh.com/
- Phone
- +1 5125190400
- Contact
- Monique Kosse
- Auditors
- BDO USA, LLP
Upcoming Events for AWH
Q1 2024 Aspira Women's Health Inc Earnings Release
Aspira Women's Health Inc Annual Shareholders Meeting
Q2 2024 Aspira Women's Health Inc Earnings Release
Similar to AWH
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Aspira Women's Health share price?
As of Today at 19:03 UTC, shares in Aspira Women's Health are trading at $3.49. This share price information is delayed by 15 minutes.
How has the Aspira Women's Health share price performed this year?
Shares in Aspira Women's Health last closed at $3.49 and the price had moved by -35.83% over the past 365 days. In terms of relative price strength the Aspira Women's Health share price has underperformed the S&P500 Index by -46.6% over the past year.
What are the analyst and broker recommendations for Aspira Women's Health?
The overall consensus recommendation for Aspira Women's Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Aspira Women's Health dividend yield?
Aspira Women's Health does not currently pay a dividend.
Does Aspira Women's Health pay a dividend?
Aspira Women's Health does not currently pay a dividend.
When does Aspira Women's Health next pay dividends?
Aspira Women's Health does not currently pay a dividend.
How do I buy Aspira Women's Health shares?
To buy shares in Aspira Women's Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aspira Women's Health?
As of the previous close price of $3.49, shares in Aspira Women's Health had a market capitalisation of $43.08m.
Where are Aspira Women's Health shares listed?
Here are the trading details for Aspira Women's Health:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AWH
What kind of share is Aspira Women's Health?
Based on an overall assessment of its quality, value and momentum Aspira Women's Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aspira Women's Health share price forecast for 2024?
The analyst consensus target price for shares in Aspira Women's Health is $5.25. That is 50.43% above the last closing price of $3.49.
Analysts covering Aspira Women's Health currently have a consensus Earnings Per Share (EPS) forecast of -$1.34 for the next financial year.
What is the trend in the Aspira Women's Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aspira Women's Health. Over the past six months, its share price has underperformed the S&P500 Index by -48.83%.
As of the last closing price of $3.49, shares in Aspira Women's Health were trading -12.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aspira Women's Health PE Ratio?
The Aspira Women's Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aspira Women's Health?
Aspira Women's Health's management team is headed by:
- James Lafrance - NEC
- Valerie Palmieri - PRE
- Robert Beechey - CFO
- Mint Merchant - GCN
- Veronica Jordan - IND
- Nicole Sandford - IND